[Use of low molecular weight heparins by dermatologists].
Maakaroun
A
A
Service d'Hématologie-Hémostase, Hôpital Trousseau, CHU, 37044 Tours Cedex 01.
Gruel
Y
Y
D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D001779:Blood Coagulation Factors / Q000378:metabolism; D002809:Chondroitin Sulfates / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D003871:Dermatan Sulfate / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004342:Drug Hypersensitivity / Q000097:blood / Q000209:etiology*; D016903:Drug Monitoring; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D006497:Heparan Sulfate / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D006801:Humans; D007279:Injections, Subcutaneous; D012307:Risk Factors; D012871:Skin Diseases / Q000097:blood / Q000188:drug therapy*; D013923:Thromboembolism / Q000097:blood / Q000188:drug therapy*
D000925:Anticoagulants; D001779:Blood Coagulation Factors; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004338:Drug Combinations; D006495:Heparin, Low-Molecular-Weight; D006497:Heparan Sulfate; C035838:danaparoid